## Javier F Torres-Roca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/80979/publications.pdf

Version: 2024-02-01

50 papers

2,640 citations

279798 23 h-index 42 g-index

55 all docs 55 docs citations

55 times ranked 2425 citing authors

#	Article	IF	CITATIONS
1	The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 635-647.	0.8	11
2	Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. Journal of Thoracic Oncology, 2021, 16, 428-438.	1.1	32
3	Letter Response. Journal of Thoracic Oncology, 2021, 16, e28-e29.	1.1	O
4	Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose. Journal of Thoracic Oncology, 2021, 16, e48-e49.	1.1	O
5	Genomically Guided Breast Radiation Therapy: A Review of the Current Data and Future Directions. Advances in Radiation Oncology, 2021, 6, 100731.	1.2	7
6	Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncology, The, 2021, 22, 1221-1229.	10.7	76
7	Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Translational Oncology, 2021, 14, 101165.	3.7	24
8	Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia, 2021, 23, 1110-1122.	<b>5.</b> 3	15
9	Radiotherapy with genomic-adjusted radiation dose – Authors' reply. Lancet Oncology, The, 2021, 22, e470-e471.	10.7	O
10	Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer TreatedÂWithÂAdjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 496-502.	0.8	24
11	Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncology, 2020, 16, 2411-2420.	2.4	2
12	Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine, 2019, 47, 163-169.	6.1	38
13	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology, 2019, 29, 111-125.	2.2	4
14	Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Reports of Practical Oncology and Radiotherapy, 2019, 24, 593-599.	0.6	13
15	Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Annals of Surgical Oncology, 2019, 26, 379-385.	1.5	36
16	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101, 274-284.	0.8	50
17	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. Journal of Thoracic Oncology, 2018, 13, 1121-1127.	1.1	59
18	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Management, 2018, 5, MMT02.	0.5	4

#	Article	IF	CITATIONS
19	Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. International Journal of Breast Cancer, 2018, 2018, 1-8.	1.2	10
20	Genomic biomarkers for precision radiation medicine $\hat{a} \in \text{``Authors''}$ reply. Lancet Oncology, The, 2017, 18, e239.	10.7	2
21	The future of personalised radiotherapy for head and neck cancer. Lancet Oncology, The, 2017, 18, e266-e273.	10.7	168
22	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 473-482.	4.9	25
23	The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro-Oncology, 2017, 19, 1145-1146.	1.2	20
24	Genomic-adjusted radiation dose – Authors' reply. Lancet Oncology, The, 2017, 18, e129.	10.7	3
25	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncology, The, 2017, 18, 202-211.	10.7	377
26	Tumour radiosensitivity is associated with immune activation in solid tumours. European Journal of Cancer, 2017, 84, 304-314.	2.8	44
27	Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. International Journal of Genomics, 2017, 2017, 1-9.	1.6	6
28	Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1399-1404.	0.8	127
29	Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. Cancer Control, 2016, 23, 21-29.	1.8	28
30	Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT Journal of Clinical Oncology, 2016, 34, 239-239.	1.6	2
31	Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. International Journal of Radiation Oncology Biology Physics, 2015, 92, 837-842.	0.8	82
32	Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiotherapy and Oncology, 2015, 117, 159-164.	0.6	75
33	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 631-638.	0.8	102
34	Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. American Journal of Health Promotion, 2015, 29, 393-401.	1.7	9
35	Differences between colon cancer primaries and metastases utilizing a molecular assay for tumor radiosensitivity and implications for potential oligometastatic SBRT patient selection Journal of Clinical Oncology, 2015, 33, 569-569.	1.6	1
36	The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget, 2015, 6, 34414-34422.	1.8	100

3

#	Article	IF	CITATIONS
37	Radiosensensitivity index prognostic for survival with adjuvant radiation in resectable pancreatic cancer Journal of Clinical Oncology, 2015, 33, 398-398.	1.6	O
38	Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. Contemporary Clinical Trials, 2014, 39, 327-334.	1.8	3
39	Personalized medicine for radiation therapy. Personalized Medicine, 2013, 10, 107-110.	1.5	O
40	Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research, 2012, 18, 5134-5143.	7.0	174
41	A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Personalized Medicine, 2012, 9, 547-557.	1.5	71
42	Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy, 2012, 4, 373-382.	2.0	33
43	New Biomarkers in Prostate Cancer: A Radiation Oncology Perspective. Radiation Medicine Rounds, 2011, 2, 1-10.	0.0	0
44	A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 489-496.	0.8	283
45	Systems Biology Modeling of the Radiation Sensitivity Network: A Biomarker Discovery Platform. International Journal of Radiation Oncology Biology Physics, 2009, 75, 497-505.	0.8	228
46	Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10. Urology, 2007, 69, 505-509.	1.0	31
47	Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: A review of the H. Lee Moffitt Cancer Center experience. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 384-390.	1.6	6
48	A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy, 2006, 5, 244-250.	0.5	30
49	Prediction of Radiation Sensitivity Using a Gene Expression Classifier. Cancer Research, 2005, 65, 7169-7176.	0.9	197
50	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. SSRN Electronic Journal, 0, , .	0.4	2